Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02265536 · ClinicalTrials.gov registry record · Phase 1
A Study of LY3022855 In Participants With Breast or Prostate Cancer
A Phase 1 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 34
- Enrollment target
NCT02265536 is a Phase 1 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 34 participants.
The verdict
NCT02265536, a Phase 1 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 34 participants
- Enrollment target
Study Summary
The main purpose of this study is to learn more about how the investigational drug, LY3022855, affects the immune system in participants with advanced breast or prostate cancer that has not responded to other treatments. Treatment may last up to 6 cycles (cycle = 6 weeks).
Interventions
- DRUG LY3022855
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2015-05-01 |
| Est. Completion | 2017-11-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02265536
The ClinicalTrials.gov registry entry for NCT02265536 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 34 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which LY3022855 is the first listed.
NCT02265536 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02265536 about?
NCT02265536 is a clinical study titled "A Study of LY3022855 In Participants With Breast or Prostate Cancer". The main purpose of this study is to learn more about how the investigational drug, LY3022855, affects the immune system in participants with advanced breast or prostate cancer that has not responded to other treatments. Treatment may last up to 6 cycles (cycle = 6 weeks).
What is the current status of trial NCT02265536?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 34 participants. The study started on 2015-05-01. Estimated completion is 2017-11-03.
What interventions are being tested in trial NCT02265536?
The interventions under investigation include: LY3022855 (DRUG).
Who is sponsoring clinical trial NCT02265536?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.